Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOMA-313 + olaparib
- Development stage
- Unknown
- Lead developer
- MOMA Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MOMA-313 + olaparib is a combination therapy consisting of MOMA-313, a first-in-class oral inhibitor of DNA polymerase theta (Polθ), and olaparib, a well-established oral small molecule inhibitor of poly (ADP-ribose) polymerase (PARP). This combination is being evaluated for the treatment of advanced or metastatic solid tumors characterized by homologous recombination deficiency (HRD), including but not limited to subtypes with BRCA1/2, ATM, PALB2, and other HR-related gene mutations. Both drugs are given orally. MOMA-313 targets tumor cells reliant on alternative DNA repair mechanisms, while olaparib impairs single-strand DNA repair by inhibiting PARP, collectively leading to increased DNA damage and cancer cell death in HRD tumors. This combination is in early clinical investigation and is not yet approved for any indication[1][3][5][7][9].
- Other names
- AZD2281AZD-2281AZD 2281KU-0059436KU0059436KU 0059436
02
Targets
Polθ HLD (Helicase domain of DNA polymerase theta)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on MOMA-313 + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOMA-313 + olaparib.